You are here
Advances in Targeted Treatment for BRAF V600-Mutant Metastatic Melanoma: Evidence-based Combination Strategies (AV)
Date: Mon. 28 Sept / 13:00 – 14:30 / Hall A4
Treatments for BRAF V600-mutant melanoma have changed dramatically including the development of combination therapies which target both BRAF and MEK. This session explores the potential benefits of dual BRAF/MEK inhibition combination therapy targeting both the oncologic driver and a downstream signalling component within the MAPK pathway through a review of the clinical evidence and real-world data as well as an exploration of patient case studies.
This Webcast and Webcast Report were supported by Novartis Oncology, all items are subject to independent peer and editorial review.
Targeted inhibition of the MAPK pathway in BRAF V600-mutant metastatic melanoma: The evolution of options (AV-1)
C. Hoeller (Austria)
Christoph Hoeller tells the story leading up to today’s treatment of BRAF V600E melanoma. He talks about the incidence and treatment of melanoma, the role of the BRAF mutation and the results of clinical trials.
C. Robert (France)
Caroline Robert provides an overview of key clinical studies for BRAF/MEK inhibitor combination therapy in metastatic melanoma, with some late results of the Phase II trial with dabrafenib and trametinib.
P. Nathan (United Kingdom)
Paul Nathan talks about two patients, both treated with dabrafenib and trametinib. The first raises issues about treating multifocal brain disease, and the second highlights the management of pyrexia.
Moderator: C. Hoeller (Austria)
Christoph Hoeller leads a panel discussion on the treatment of metastatic melanoma, with Caroline Robert and Paul Nathan.